Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Tumor

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44359   clinical trials with a EudraCT protocol, of which   7383   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    6,808 result(s) found for: Tumor. Displaying page 108 of 341.
    «« First « Previous 104  105  106  107  108  109  110  111  112  Next» Last»»
    EudraCT Number: 2021-003751-42 Sponsor Protocol Number: ICH-013-UroNEOadI Start Date*: 2022-01-25
    Sponsor Name:IRCCS ISTITUTO CLINICO HUMANITAS
    Full Title: Randomized phase III clinical trial of Neo-Adjuvant Intravesical mitomycin C (MMC) treatment in patients with primary treatment-naïve vesical neoplasms.
    Medical condition: Patients with primary treatment-naïve vesical neoplasms.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10046702 Urogenital neoplasm LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-016782-28 Sponsor Protocol Number: GMIHO-009/2009/AG52 Start Date*: 2010-09-15
    Sponsor Name:GMIHO Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie mbH
    Full Title: Panitumimab in combination with radiotherapy in patients with locally advanced RAS wildtype rectal cancer (clinical stages II and III)
    Medical condition: Locally advanced RAS wildtype rectal cancer (clinical stage II and III)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038050 Rectal cancer stage III PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038049 Rectal cancer stage II PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-002625-35 Sponsor Protocol Number: CALGB80802 Start Date*: 2013-09-23
    Sponsor Name:All Ireland Co-operative Oncology Research Group (ICORG)
    Full Title: Phase III Randomized Study Of Sorafenib Plus Doxorubicin Versus Sorafenib In Patients With Advanced Hepatocellular Carcinoma (HCC)
    Medical condition: Advanced or Metastatic Hepatocellular Carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-004608-22 Sponsor Protocol Number: 17-PP-21 Start Date*: 2018-05-22
    Sponsor Name:CHU de Nice
    Full Title: Open, prospective, single-center study evaluating the efficacy and safety of 0.05% ingénol mebutate (Picato® 500) in the treatment of basal cell carcinoma Study "PICABAS"
    Medical condition: Patients with one or more basal cell carcinoma superficial, or nodular, trunk or limb
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10007284 Carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-002156-14 Sponsor Protocol Number: OCS–3rdLINE/OCCASIONE-STUDY Start Date*: 2008-09-17
    Sponsor Name:FUNDATION OF EXPERIMENTAL AND CLINICAL ONCOLOGY
    Full Title: A phase II non-randomised, open-label, single-arm study to assess the efficacy, safety and tolerability of Nexavar ® (Sorafenib) monotherapy as third line therapy in patients with progressed ovaria...
    Medical condition: 1. progressed ovarian epithelial cancer 2. primary peritoneal cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033128 Ovarian cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-000105-20 Sponsor Protocol Number: 0316-ASG Start Date*: 2017-10-02
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: Neoadjuvant anti PD-1 immunotherapy in resectable non-small cell lung cancer
    Medical condition: non-small cell lung cancer (NSCLC), resectable
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029520 Non-small cell lung cancer stage IIIA PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029518 Non-small cell lung cancer stage II PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-002449-13 Sponsor Protocol Number: S65525 Start Date*: 2021-07-30
    Sponsor Name:University Hospitals Leuven (UZ Leuven)
    Full Title: Visualisation of Indocyanine Green in Primary and Interval Debulking for Ovarian Cancer
    Medical condition: Advanced stage high-grade serous epithelial ovarian cancer: FIGO stage IIIb, IIIc and IV
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-000921-61 Sponsor Protocol Number: NONK-3/NOA-12 Start Date*: 2012-04-25
    Sponsor Name:Ruprecht-Karls-University Heidelberg, Medical Faculty
    Full Title: A phase I/II, randomized, open-label, multi-centre study of BIBF1120 + reirradiation (R-RT) versus reirradiation in the treatment of patients with first or second progression of glioblastoma
    Medical condition: glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-002206-20 Sponsor Protocol Number: MK-3475-052 Start Date*: 2014-12-22
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase II Clinical Trial of Pembrolizumab (MK-3475) in Subjects with Advanced/Unresectable or Metastatic Urothelial Cancer
    Medical condition: advanced/unresectable (inoperable) or metastatic urothelial cancer of the renal pelvis, ureter, bladder, or urethra.
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10046714 Urothelial carcinoma bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DK (Completed) IT (Completed) IE (Completed) GB (GB - no longer in EU/EEA) HU (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2015-001537-24 Sponsor Protocol Number: EMR100070-005 Start Date*: 2015-12-14
    Sponsor Name:Merck KGaA
    Full Title: A Phase III, open-label, multicenter trial of avelumab (MSB0010718C) versus platinum based doublet as a first line treatment of recurrent or Stage IV PD L1+ non small cell lung cancer
    Medical condition: First Line Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Prematurely Ended) DE (Completed) PT (Completed) LT (Completed) BE (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) ES (Temporarily Halted) HU (Completed) PL (Completed) NL (Completed) FR (Completed) DK (Completed) BG (Completed) HR (Completed) CY (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-001080-36 Sponsor Protocol Number: 20150195 Start Date*: 2016-11-17
    Sponsor Name:Amgen Incorporated
    Full Title: A Phase 1b/2 Study Assessing Safety and Anti-tumor Activity of AMG 820 in Combination With Pembrolizumab in Select Advanced Solid Tumors
    Medical condition: Advanced Colorectal cancer (CRC), pancreatic cancer or non-small cell lung cancer (NSCLC), and other indications dependent on emerging data
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049280 Solid tumour LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033605 Pancreatic cancer metastatic LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033604 Pancreatic cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-002807-24 Sponsor Protocol Number: CA018-003 Start Date*: 2017-08-11
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants with Advanced Gastric Cancer - Master Revprot05 dated 13-Sep-2019 - Sub-protocol A Revpro...
    Medical condition: Advanced Gastric Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-002481-13 Sponsor Protocol Number: AG881-C-004 Start Date*: 2020-10-27
    Sponsor Name:Institut de Recherches Internationales Servier (I.R.I.S)
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation
    Medical condition: Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018338 Glioma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) GB (GB - no longer in EU/EEA) NL (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-004076-34 Sponsor Protocol Number: 7487-CL-0209 Start Date*: 2014-02-27
    Sponsor Name:Astellas Pharma Global Development, Inc.
    Full Title: A phase II open-label rollover study for subjects that have participated in an Astellas sponsored linsitinib trial
    Medical condition: Solid tumors
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001388 Adrenocortical carcinoma PT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065147 Malignant solid tumor LLT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) PL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-003929-22 Sponsor Protocol Number: ICON7 Start Date*: 2006-12-15
    Sponsor Name:Medical Research Council
    Full Title: ICON7 - A randomised, two-arm, multicentre Gynaecologic Cancer InterGroup trial of adding bevacizumab to standard chemotherapy (carboplatin and paclitaxel) in patients with epithelial ovarian cancer.
    Medical condition: Following initial surgery (either debulking cytoreductive surgery or a biopsy if the patient has FIGO stage IV disease and there is no planned surgery before disease progression) patients with new...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10033128 Ovarian cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) FI (Completed) DE (Completed) DK (Completed) SE (Completed) ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-016468-35 Sponsor Protocol Number: D8480C00067 Start Date*: 2016-03-29
    Sponsor Name:AstraZeneca AB
    Full Title: A randomised, double-blind, phase III efficacy and safety study of cediranib (RECENTIN™ ) when added to cisplatin plus a fluoropyrimidine, compared with cisplatin plus a fluoropyrimidine alone, in ...
    Medical condition: Gastric cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10017758 Gastric cancer LLT
    12.1 10017760 Gastric cancer NOS LLT
    12.1 10017766 Gastric cancer stage IV NOS LLT
    12.1 10017767 Gastric cancer stage IV with metastases LLT
    12.1 10017768 Gastric cancer stage IV without metastases LLT
    12.1 10061967 Gastric cancer stage IV LLT
    12.1 10063916 Metastatic gastric cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-015970-36 Sponsor Protocol Number: D0810C00041 Start Date*: 2010-02-22
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Open-Label, Randomised, Comparative, Multicentre Study to Compare the Efficacy and tolerability of Oral Olaparib in combination with Carboplatin and Paclitaxel Versus Carboplatin and Pa...
    Medical condition: Serous ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    12.0 10033128 Ovarian cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing) DE (Completed) CZ (Completed) BE (Completed) ES (Ongoing) IT (Completed) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2020-003652-32 Sponsor Protocol Number: ISA101b-OPC-03-19 Start Date*: 2021-04-13
    Sponsor Name:ISA Therapeutics B.V.
    Full Title: A Phase II Study of cemiplimab, an anti-PD-1 monoclonal antibody, and ISA101b vaccine in patients with recurrent/metastatic HPV16- positive Oropharyngeal Cancer who have experienced disease progres...
    Medical condition: Recurrent/metastatic HPV16- positive Oropharyngeal Cancer (OPC)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10031098 Oropharyngeal cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FR (Completed) BE (Completed) CZ (Completed) ES (Ongoing) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000125-27 Sponsor Protocol Number: EORTC-1976-STBSG-QLG-ETF Start Date*: 2022-05-31
    Sponsor Name:EORTC AISBL/IVZW
    Full Title: TOLERANCE: a 3 arm randomized study on healTh-related quality Of Life of EldeRly pAtients with advaNced soft tissue sarComa undergoing doxorubicin every three weeks or doxorubicin weekly or cycloph...
    Medical condition: Advanced/metastatic soft tissue sarcoma
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) ES (Prematurely Ended) NL (Completed) CY (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-002669-38 Sponsor Protocol Number: 0822-016 Start Date*: 2006-12-07
    Sponsor Name:Merck & Co Inc.
    Full Title: A Phase II Study to Assess the Safety, Tolerability, and Efficacy of MK-0822 (Cathepsin-K Inhibitor) in the Treatment of Women with Breast Cancer and Established Bone Metastases (MBD)
    Medical condition: Metastatic Bone Disease (MBD)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10027452 Metastases to bone LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) NO (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 104  105  106  107  108  109  110  111  112  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Oct 02 21:04:10 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA